FDA

6 statements across 4 episodes · 1 bullish · 3 bearish · 4 people on the record · first statement Jun 1, 2020 by Clark Futch · across every show →

Everything said about FDA, oldest first

Jun 1, 2020
Assertion Supported
Futch: US Orphan Drug legislation grants seven years of market exclusivity
“In order to make it economically attractive, the government put in legislation that said if you do it, and you have to go through an FDA regulatory review, We will give you seven years of exclusivity where we will not approve another drug that does the same th…”
Clark Futch Jun 1, 2020 ▶ 36:56 Clarke Futch – Healthcare Royalty Partners (First Meeting, EP.20)
Jun 1, 2020
Disclosure
Futch: 90% of Healthcare Royalty Partners' investments are FDA-approved products
“And that's the key for us, 90% of what we do are products that have been approved by the FDA”
Clark Futch Jun 1, 2020 ▶ 14:54 Clarke Futch – Healthcare Royalty Partners (First Meeting, EP.20)
Mar 7, 2022 negative
Assertion Contradicted
Lamont: By 2000 there were 3,000 public biotech companies and 5 approved products
“That there were 3000 public biotech companies, and only five approved products.”
Annie Lamont Mar 7, 2022 ▶ 14:36 Annie Lamont – A Lifetime in Venture, Venture is Eating the Investment World 9 (Capital Allocators, EP. 238)
Mar 7, 2022 negative
Disclosure
Oak HC/FT refuses to invest directly in FDA-risk biotech
“In terms of directly investing into biotech and life sciences companies that take FDA risk, we won't do that.”
Annie Lamont Mar 7, 2022 ▶ 20:28 Annie Lamont – A Lifetime in Venture, Venture is Eating the Investment World 9 (Capital Allocators, EP. 238)
Apr 24, 2023 negative
Insight
Rod Wong: FDA staff turnover is driving more conservative regulatory decisions
“COVID actually had a major impact on how the FDA functions. They moved heaven and earth to get those vaccines and the first handful of drugs approved. It burned a lot of people out. And so you had tremendous turnover at FDA and there's a whole training process…”
Rod Wong Apr 24, 2023 ▶ 53:14 Rod Wong – Empty Rooms: Innovation in Biotech at RTW (Capital Allocators, EP. 310)
Jun 30, 2025 bullish
Opinion
Barth: Dislocated biotech sector presents massive multi-asset investment opportunities
“One of the places where we see public, private, and credit incredibly dislocated, unloved, and where we think there's huge opportunity is biotech. It has been such a bubble through the pandemic where biotech and vaccines were going to solve everything, and now…”
Brett Barth Jun 30, 2025 ▶ 39:12 Friends Reunion 3 – Five Allocators Riff on Investing (EP.454)
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 700 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.